Eli Lilly reported a strong third quarter with revenue of $17.60 billion and adjusted EPS of $7.02, both well above expectations, and raised full-year guidance. Mounjaro and Zepbound drove core growth, generating $6.52 billion and $3.57 billion respectively, lifting revenue 54% and volume 62%. Gross profit rose 57% to $14.59 billion, operating income jumped 62% to $7.37 billion, and net income surged 475% to $5.58 billion. The company advanced orforglipron in four additional Phase 3 trials and targets global obesity submissions by year-end, while gaining FDA approval for Inluriyo. Manufacturing expansion in Virginia, Texas and Puerto Rico aims to support sustained demand.
"Lilly's incretin drugs drove the earnings beat. Mounjaro, the company's diabetes treatment, generated $6.52 billion in quarterly revenue, up 109% year-over-year. Zepbound, its obesity medication, contributed $3.57 billion, surging 184% year-over-year. Combined, these two products accounted for the bulk of revenue growth and explain why the company's top line expanded 54% to $17.60 billion against consensus expectations of $16.07 billion. Volume increased 62% in the quarter, signaling sustained demand rather than pricing dynamics alone."
"Beyond current revenue drivers, Lilly advanced orforglipron through four additional Phase 3 trials this quarter. The company now targets global obesity submissions by year-end, positioning the next-generation incretin candidate as a potential catalyst heading into 2026. Manufacturing capacity expansion is underway. Lilly is building new facilities in Virginia and Texas while expanding its Puerto Rico site."
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]